Attached files
file | filename |
---|---|
EX-21.1 - EX-21.1 - TCR2 THERAPEUTICS INC. | d555750dex211.htm |
EX-10.4 - EX-10.4 - TCR2 THERAPEUTICS INC. | d555750dex104.htm |
EX-10.2 - EX-10.2 - TCR2 THERAPEUTICS INC. | d555750dex102.htm |
EX-5.1 - EX-5.1 - TCR2 THERAPEUTICS INC. | d555750dex51.htm |
EX-4.2 - EX-4.2 - TCR2 THERAPEUTICS INC. | d555750dex42.htm |
EX-3.5 - EX-3.5 - TCR2 THERAPEUTICS INC. | d555750dex35.htm |
EX-3.4 - EX-3.4 - TCR2 THERAPEUTICS INC. | d555750dex34.htm |
EX-3.3 - EX-3.3 - TCR2 THERAPEUTICS INC. | d555750dex33.htm |
EX-3.2 - EX-3.2 - TCR2 THERAPEUTICS INC. | d555750dex32.htm |
EX-1.1 - EX-1.1 - TCR2 THERAPEUTICS INC. | d555750dex11.htm |
S-1/A - S-1/A - TCR2 THERAPEUTICS INC. | d555750ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
TCR2 Therapeutics Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading Experts in the prospectus.
(signed) KPMG LLP
Cambridge, Massachusetts
February 1, 2019